Gene
MYC
MYC is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (130), Actionable biomarkers (6), Trial mentions (382), and 7 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
2 more sections with rows · 2 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention MYC. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers. Not plotted: 1 with no date at all.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 3 dated before 1990 and 54 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 40 of 8,738 | 0.46% | not measured | |
| 2025 | 42 of 8,875 | 0.47% | not measured | |
| 2024 | 40 of 8,597 | 0.47% | not measured | |
| 2023 | 39 of 8,275 | 0.47% | 162 of 11,460 | 1.41% |
| 2022 | 39 of 8,285 | 0.47% | 164 of 13,598 | 1.21% |
| 2021 | 38 of 8,692 | 0.44% | 181 of 15,045 | 1.20% |
| 2020 | 33 of 7,640 | 0.43% | 167 of 14,459 | 1.15% |
| 2019 | 26 of 7,300 | 0.36% | 142 of 12,159 | 1.17% |
| 2018 | 24 of 6,927 | 0.35% | 156 of 11,854 | 1.32% |
| 2017 | 14 of 6,558 | 0.21% | 153 of 11,595 | 1.32% |
Showing 10 of 37 years.
Assay-provider ledger (130)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Bioneer (Daejeon, Korea) - Exicycler TM 96 instrument | Reagent supplier | Clinical validation | 1 | May 01, 2026 |
| Invitrogen (Carlsbad, CA, USA) - TRIzol reagent | Reagent supplier | Clinical validation | 1 | May 01, 2026 |
| Roche Co. Ltd. - SYBR Green Master Mix | Unclassified | Clinical validation | 1 | May 01, 2026 |
| Thermo (Lithuania) - RevertAid First Strand cDNA Synthesis Kit | Reagent supplier | Clinical validation | 1 | May 01, 2026 |
| University of Minnesota Genomics Center | Not a company | Clinical validationAnalytical validation | 1 | April 01, 2026 |
Showing 5 of 130 assay-provider companies.
Actionable biomarkers (6)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| MYC amplification | Temozolomide | response-associated | colorectal adenocarcinoma | Cancer Genome Interpreter |
| MYC amplification | Bet Inhibitors | response-associated | multiple myeloma | Cancer Genome Interpreter |
| MYC amplification | Bet Inhibitors | response-associated | neuroblastoma | Cancer Genome Interpreter |
| MYC amplification | Cdk7 Inhibitors | response-associated | neuroblastoma | Cancer Genome Interpreter |
| MYC amplification | Fact Inhibitors | response-associated | neuroblastoma | Cancer Genome Interpreter |
Showing 5 of 6 actionable-biomarker assertions.
Trial mentions (382)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT06777082 | Trial biospecimen (AACT) |
| NCT06652152 | Trial biospecimen (AACT) |
| NCT03603951 | Trial eligibility (AACT) |
| NCT05800366 | Trial eligibility (AACT) |
| NCT06356129 | Trial eligibility (AACT) |
Showing 5 of 382 trial mentions.
Target-disease associations (1,033)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 1-palmitoleoylglycerol (16:1) measurement | measurement | GWAS credible sets |
| 46,XX gonadal dysgenesis | endocrine system disease | Mouse knockout (IMPC) |
| 46,XX sex reversal 1 | endocrine system disease | Mouse knockout (IMPC) |
| 46,XX testicular disorder of sex development | endocrine system disease | Mouse knockout (IMPC) |
| 46,XY complete gonadal dysgenesis | cardiovascular disease | Mouse knockout (IMPC) |
Showing 5 of 1,033 associations.
Vendor sourcing (1,221)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| ADC Therapeutics SA | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * PART 1: Subjects must have a histologically confirmed diagnosis of diffuse large B-cell lymphoma including diffuse large B-cell lymphoma (DLBCL) not oth... | View trial NCT05228249 |
| ADC Therapeutics SA | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * Subject aged ≥ 18 years. * Intended to receive commercial CD19-directed CAR-T cell therapy (axi-cel and liso-cel). * Need for bridging therapy as deemed... | View trial NCT06788964 |
| ADC Therapeutics SA | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * Histologically or cytologically confirmed untreated DEL and DHL diffuse large B-cell lymphoma (DLBCL) meeting the World Health Organization (WHO) criter... | View trial NCT05600686 |
| ADC Therapeutics SA | Trial collaborator | Mentioned in trial textTrial free-text mention | MYC | View trial NCT05600686 |
| ADC Therapeutics SA | Trial collaborator | Mentioned in trial textTrial free-text mention | MYC | View trial NCT05228249 |
Showing 5 of 1,221 sourcing records.
Trial-cited literature (2,043)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Fecal microbiota transplantation promotes type 2 mucosal immune responses with colonic epithelium proliferation in patients with recurrent Clostridioides difficile. | JCI insight | 2026 | 5 |
| Risk stratification of patients with diffuse large B-cell lymphoma using plasma NMR-based metabolomics at diagnosis. | Blood advances | 2026 | 2 |
| Proteomic footprint of serum urate concentration and urate transporter <i>ABCG2</i> dysfunctional polymorphism: a cross-sectional study. | RMD open | 2026 | 0 |
| Precision Medicine Program in Chinese Pediatric Patients With Sarcoma. | JCO precision oncology | 2026 | 0 |
| Phase 1 trial of durvalumab (anti-PD-L1) combined with lenalidomide in relapsed/refractory cutaneous T-cell lymphoma. | Blood advances | 2025 | 13 |
Showing 5 of 2,043 papers.
Protein variant mentions (23)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A416S | 1 | 2023 | PMID 36639200 |
| p.C25N | 1 | 2014 | PMID 25056707 |
| p.D248N | 1 | 2020 | PMID 31820118 |
| p.G509R | 1 | 2020 | PMID 31820118 |
| p.I1009A | 1 | 2008 | PMID 18648664 |
Showing 5 of 23 variants.
Human sample screening reference (1)
Shown in this order: alphabetical by variant.
| Variant | GDC project | Disease / site | Affected cases | Profiled cases | Observed frequency | 95% interval |
|---|---|---|---|---|---|---|
| p.P57T | CGCI-BLGSP | Mature B-Cell Lymphomas; Hematopoietic and reticuloendothelial systems | 1 | 263 | 0.38% | 0.07% to 2.12% |
Literature-extracted relations (272)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| LENALIDOMIDE | Chemical | negative_correlate |
A multicenter phase 1/2 trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated DLBCL. | 2025 |
| Homoharringtonine | Chemical | negative_correlate |
Homoharringtonine inhibits the NOTCH/MYC pathway and exhibits antitumor effects in T-cell acute lymphoblastic leukemia. | 2024 |
| PIOGLITAZONE | Chemical | negative_correlate |
PPARγ agonist inhibits c-Myc-mediated colorectal cancer tumor immune escape. | 2023 |
| FULVESTRANT | Chemical | associate |
Clinical efficacy of fulvestrant versus exemestane as first-line therapies for Chinese postmenopausal oestrogen-receptor positive /human epidermal growth factor receptor 2 -advanced breast cancer (FRIEND study). | 2023 |
| Irinotecan | Chemical | negative_correlate |
SN-38, an active metabolite of irinotecan, enhances anti-PD-1 treatment efficacy in head and neck squamous cell carcinoma. | 2023 |
Showing 5 of 272 relation assertions.
Organizations publishing (1,070)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Dana-Farber Cancer Institute | Other | 103 | 2005 to 2025 |
| Government of the United States of America | Government | 100 | 2008 to 2024 |
| Memorial Sloan Kettering Cancer Center | Hospital | 100 | 2004 to 2025 |
| The University of Texas System | Academic | 96 | 2006 to 2025 |
| Harvard Medical School | Academic | 87 | 2009 to 2025 |
Showing 5 of 1,070 organizations.
Where MYC appears
- animal disease
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of ear
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
926 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions and fda biomarker qualification projects.